Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.
- ITL orders 1,000 Felix™ cartridges amid MENA expansion
- Hamad Medical Corporation orders second Felix™ console
- New markets UAE and Kuwait join repeat cartridge orders
- Turkey orders expected post-regulatory approval in July
- 400 cartridges dispatched immediately, 600 more in October
Institutional Endorsement Drives Repeat Orders in Qatar
Memphasys Limited (ASX:MEM) has scored a significant commercial milestone with International Technical Legacy (ITL), its exclusive Middle East and North Africa distributor, placing an order for 1,000 Felix™ cartridges. Central to this surge is Qatar’s Hamad Medical Corporation (HMC), the country’s largest IVF institution, which has not only continued its repeat cartridge orders but also committed to a second Felix™ console. This move effectively doubles HMC’s capacity to use the Felix™ System, signalling a firm institutional endorsement and embedding the technology as a clinical standard in Qatar’s fertility treatment landscape.
Broadening Footprint Across MENA with New Market Penetration
The order spans both established and emerging markets, with 400 cartridges earmarked for immediate dispatch to Qatar, the United Arab Emirates, and Kuwait. These last two markets have transitioned from initial evaluations to committed procurement, reflecting growing regional adoption. The remaining 600 cartridges are scheduled for delivery in October 2026, supporting sustained demand from existing clients. This expanding footprint beyond a single anchor site highlights the scaling commercial traction of Felix™ within ITL’s network and reinforces Memphasys’ confidence in its recurring revenue model and cashflow visibility. This momentum builds on the company’s recent multi-year contracts secured across MENA and Europe.
Turkey and Regional Expansion Await Regulatory Green Light
Turkey, added to the ITL distribution agreement following CE Mark approval, is poised to become the next growth market with regulatory registration expected imminently. Orders from Turkey are anticipated to commence in July, with further expansion planned into Egypt, Bahrain, and Jordan later in the year. This regulatory progress aligns with Memphasys’ broader strategy of disciplined, clinic-by-clinic adoption, a model that has underpinned its commercial rollout across multiple territories. The company’s approach echoes its recent global commercial scale-up efforts, which emphasise recurring cartridge sales and regulatory approvals as key growth drivers.
Commercial Outlook and Pipeline Development
Memphasys anticipates several near-term catalysts: the immediate dispatch of 400 cartridges, the unlocking of Turkish market sales upon regulatory approval, and the scaling of Felix™ throughput at HMC with the new console. The company is also in advanced negotiations with prospective clients and partners across existing and new jurisdictions, signalling a robust pipeline. This disciplined expansion strategy, supported by six local commercial partners across the MENA region, aims to accelerate sales and entrench Felix™ as a global standard in sperm preparation for assisted reproduction.
Bottom Line?
Memphasys’ growing MENA footprint and institutional adoption suggest a solid foundation for recurring revenue, but regulatory approvals in Turkey and other markets remain key upcoming milestones.
Questions in the middle?
- How quickly will regulatory approvals in Turkey and other MENA markets translate into confirmed orders?
- What impact will the second Felix™ console have on throughput and revenue at Hamad Medical Corporation?
- How will Memphasys manage scaling production and distribution to meet accelerating demand across diverse MENA territories?